Landmark study shows caredx's heartcare outperforms dd-cfdna alone in identifying rejection and patients experienced excellent outcomes with fewer biopsies

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the shore (surveillance heartcare outcomes registry) study, one of the largest heart transplant studies of its kind, published in the journal of heart and lung transplantation.
CDNA Ratings Summary
CDNA Quant Ranking